Literature DB >> 3666000

The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels.

P Lissoni1, A Bastone, R Sala, R Mauri, F Rovelli, S Viviani, E Bajetta, D Esposti, G Esposti, L di Bella.   

Abstract

In order to investigate the pineal function and its relation with the hypophysis in human neoplasms, melatonin and GH serum levels were determined in 63 patients, 42 affected by solid tumours and 21 by lymphoma or leukaemia. In women with breast cancer PRL was also measured. Melatonin, GH and PRL were evaluated in 52 healthy subjects acting as controls. The oncological patients showed significantly higher mean melatonin serum levels than the control subjects. Mean melatonin values were lower in patients with solid tumours who had metastases, than in cases without metastases. Chemotherapy caused an evident decrease in melatonin levels. Surgery was followed by a fall in melatonin in patients without metastases. Mean GH serum levels observed in oncological patients were similar to those in control subjects and were not influenced by therapy. PRL levels were within the normal range in women suffering from breast cancer.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3666000     DOI: 10.1016/0277-5379(87)90340-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  10 in total

1.  Urinary 6-Sulphatoxymelatonin levels and risk of breast cancer in premenopausal women: the ORDET cohort.

Authors:  Eva S Schernhammer; Franco Berrino; Vittorio Krogh; Giorgio Secreto; Andrea Micheli; Elisabetta Venturelli; Sara Grioni; Christopher T Sempos; Adalberto Cavalleri; Holger J Schünemann; Sabrina Strano; Paola Muti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

Review 2.  Circulating melatonin and the risk of breast and endometrial cancer in women.

Authors:  Akila N Viswanathan; Eva S Schernhammer
Journal:  Cancer Lett       Date:  2008-12-12       Impact factor: 8.679

3.  Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women.

Authors:  Eva S Schernhammer; Franco Berrino; Vittorio Krogh; Giorgio Secreto; Andrea Micheli; Elisabetta Venturelli; Sabina Sieri; Christopher T Sempos; Adalberto Cavalleri; Holger J Schünemann; Sabrina Strano; Paola Muti
Journal:  J Natl Cancer Inst       Date:  2008-06-10       Impact factor: 13.506

4.  Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses' Health Study cohort.

Authors:  Eva S Schernhammer; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

Review 5.  Melatonin: does it have utility in the treatment of haematological neoplasms?

Authors:  Tian Li; Zhi Yang; Shuai Jiang; Wencheng Di; Zhiqiang Ma; Wei Hu; Fulin Chen; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-09-09       Impact factor: 8.739

Review 6.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

7.  Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.

Authors:  Lulu Mao; Lin Yuan; Lauren M Slakey; Frank E Jones; Matthew E Burow; Steven M Hill
Journal:  Breast Cancer Res       Date:  2010-12-17       Impact factor: 6.466

8.  Growth inhibitory and cytotoxic effects of melatonin and its metabolites on human tumour cell lines in vitro.

Authors:  S A Shellard; R D Whelan; B T Hill
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

9.  Melatonin anticancer effects: review.

Authors:  Giuseppe Di Bella; Fabrizio Mascia; Luciano Gualano; Luigi Di Bella
Journal:  Int J Mol Sci       Date:  2013-01-24       Impact factor: 5.923

10.  Seasonal changes in serum melatonin in women with previous breast cancer.

Authors:  I M Holdaway; B H Mason; E E Gibbs; C Rajasoorya; K D Hopkins
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.